In the original article, there was an error. In Gültekin's article, Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas, he found that TIMP-2 is lowly expressed in more clinical samples from invasive pituitary adenoma, which was incorrectly cited by us to prove the opposite.
A correction has been made to the section Degradation and Remodeling of ECM byMatrix Metalloproteinases Family, paragraph two:
“MMP-9 is the first matrix metalloproteinase found to have a significantly higher expression level in pituitary adenomas invaded to cavernous sinus (68). However, TIMP-1 was undetectable by immunochemistry staining in all samples (69). The correlation between MMP-9 overexpression and invasiveness of pituitary adenomas has been verified by many researchers in human pituitary adenoma specimens (70–75) as well as cell lines (76). Later studies showed that high expression levels of EMMPRIN (77, 78), MMP-2 (71, 75, 79), and MMP-14 (80, 81) and low expression levels of TIMP-2 (82, 83), TIMP-3 (82, 84), and RECK (85) were also correlated with invasiveness. There is a report that found TIMP-2 have higher expression in more patients of invasive prolactinomas then non-invasive ones (74), most of the aforementioned studies were performed on patients with prolactinoma or mixed patients of all secreting types, the contradicting results of TIMP-2 indicating that different types of pituitary adenoma might have distinct signaling pathways regarding to invasiveness. However, no statistical difference in the MMP-9 expression level between invasive and non-invasive non-functioning pituitary adenomas could be found (86).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
angiogenesis, endocrinology, invasiveness, molecular network, pituitary adenoma
Citation
Yang Q and Li X (2019) Corrigendum: Molecular Network Basis of Invasive Pituitary Adenoma: A Review. Front. Endocrinol. 10:657. doi: 10.3389/fendo.2019.00657
Received
28 June 2019
Accepted
11 September 2019
Published
24 September 2019
Volume
10 - 2019
Edited and reviewed by
Adam Mamelak, Cedars-Sinai Medical Center, United States
Updates
Copyright
© 2019 Yang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xuejun Li lxjneuro@csu.edu.cn
This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.